• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

Pain Management

Virpax to pursue over-the-counter pathway for topical spray treatment for osteoarthritis pain

June 27, 2022 By Sean Whooley

Virpax Pharmaceuticals (Nasdaq:VRPX) announced today that it will pursue a direct to over-the-counter (OTC) regular pathway for Epoladerm. Berwyn, Pennsylvania–based Virpax designed the Epoladerm investigational pre-filled topical spray analgesic product for the non-addictive management of chronic pain associated with osteoarthritis (OA) of the knee. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Business/Financial News, Drug-Device Combinations, Food & Drug Administration (FDA), Pain Management, Pharmaceutical, Regulatory/Compliance Tagged With: Virpax Pharmaceuticals

Vivera adds two industry veterans to its technology advisory board

June 23, 2022 By Sean Whooley

Vivera announced today that it added Robert Massoudi and Bryan Hughes to its technology advisory board. Massoudi and Hughes will support Newport Beach, California-based Vivera in its product and software development initiatives while forging strategic partnerships for Zicoh, the company’s electronic dose-controlled medication delivery system designed to improve prescription drug adherence, including medications with a higher […]

Filed Under: Business/Financial News, Drug Pumps, Drug-Device Combinations, Pain Management, Pharmaceutical Tagged With: Personnel Moves, Vivera

InfuSystem, Ventis Pharma enter pain management marketing deal

June 14, 2022 By Sean Whooley

InfuSystem (NSYE:INFU) announced today that it entered into a national sales and marketing agreement with Ventis Pharma. Rochester Hills, Michigan-based InfuSystem’s partnership with Ventis will focus on sales and marketing for the latter’s patented Endura-Kit brand of Enduracaine, a local anesthetic compound. The kit consists of three non-opioid drugs: tetracaine, lidocaine and epinephrine. Get the full […]

Filed Under: Business/Financial News, Drug-Device Combinations, Pain Management, Pharmaceutical Tagged With: InfuSystem, Ventis Pharma

Early study supports experimental hydrogel injection for chronic low back pain

June 13, 2022 By Sean Whooley

A study demonstrated that an experimental hydrogel formulation was safe and effective in substantially relieving chronic low back pain. Research presented at the Society of Interventional Radiology Annual Scientific Meeting in Boston supported the hydrogel, which was injected into spinal discs in an effort to relieve chronic low back pain caused by degenerative disc disease […]

Filed Under: Clinical Trials, Drug-Device Combinations, Orthopedics, Pain Management, Spine Tagged With: hydrogel, hydrogels, ReGelTec

NeuroMetrix’s Quell neuromodulation device wins FDA de novo nod to treat fibromyalgia

May 19, 2022 By Sean Whooley

NeuroMetrix (Nasdaq:NURO) announced today that it received FDA de novo authorization for its Quell neuromodulation device. Quell received the authorization as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity. Quell garnered FDA breakthrough device designation to treat fibromyalgia in July 2021. Much like when it received the breakthrough nod, […]

Filed Under: Business/Financial News, Digital Health, Featured, Food & Drug Administration (FDA), Implants, Neurological, Neuromodulation/Neurostimulation, News Well, Pain Management, Regulatory/Compliance Tagged With: Neurometrix

Avanos rises as Q1 earnings match Wall Street projections

May 4, 2022 By Sean Whooley

Avanos Medical (NYSE:AVNS) shares ticked up today on first-quarter results that just about matched the consensus forecast. The Alpharetta, Georgia–based pain management and chronic care device company posted profits of $5.8 million, or 12¢ per share, on sales of $197.4 million for the three months ended March 31, 2022, for a bottom-line gain from losses […]

Filed Under: Business/Financial News, Catheters, Drug Pumps, Drug-Device Combinations, MassDevice Earnings Roundup, Neuromodulation/Neurostimulation, Pain Management, Wall Street Beat Tagged With: Avanos Medical, Avanos Medical (formerly Halyard Health)

Stevanato Group, Bexson expand partnership for wearable drug delivery device

April 29, 2022 By Sean Whooley

Stevanato Group and Bexson Biomedical announced today that they agreed to expand their drug delivery collaboration. Under the agreement, Bexson has access to the use of a customized version of Stevanato’s SG EZ-be Pod wearable delivery system so it can develop new therapeutics for treating an array of mental health conditions, including treatment-resistant depression and post-traumatic stress disorder […]

Filed Under: Business/Financial News, Drug Pumps, Drug-Device Combinations, Neurological, Pain Management Tagged With: Bexson Biomedical, stevanato group

Ear-puffing device for migraine treatment wins FDA breakthrough designation

April 28, 2022 By Jim Hammerand

A handheld device that treats migraine attacks with puffs of air in a patient’s ears has been designated a breakthrough device by the FDA. Tempe, Arizona-based Nocira said it is the first company to announce breakthrough device designation for treating migraine attacks in both chronic and non-chronic migraine patients ages 18 and up. The device […]

Filed Under: Blog, Clinical Trials, Featured, Food & Drug Administration (FDA), Neurological, Neuromodulation/Neurostimulation, News Well, Pain Management, Regulatory/Compliance Tagged With: FDA, migraines, Nocira

NeuroMetrix revenues rise in Q1

April 26, 2022 By Sean Whooley

NeuroMetrix (Nasdaq:NURO) shares dipped today on first-quarter results that saw losses despite year-over-year revenue growth. The Woburn, Massachusetts–based company posted losses of $958,562, or 14¢ per share, on sales of $2.3 million for the three months ended March 31, 2022, for a bottom-line slide deeper into the red on sales growth of 6.8%. NeuroMetrix’s biggest […]

Filed Under: Bioelectronic Medicine, Business/Financial News, Featured, Implants, MassDevice Earnings Roundup, Neurological, Neuromodulation/Neurostimulation, News Well, Pain Management, Wall Street Beat Tagged With: Neurometrix

Abbott launches upgraded digital health app for neurostimulation

April 25, 2022 By Sean Whooley

Abbott (NYSE:ABT) announced today that it launched an upgraded version of its NeuroSphere myPath digital health app. The Abbott Park, Illinois-based company designed the upgraded app with enhanced functionality to help doctors more closely track their patients as they trial Abbott neurostimulation devices to address their chronic pain. According to a news release, Abbott’s digital […]

Filed Under: Business/Financial News, Clinical Trials, Digital Health, Featured, Health Technology, Neurological, Neuromodulation/Neurostimulation, News Well, Pain Management, Patient Monitoring, Software / IT Tagged With: Abbott

Medtronic survey says pandemic has negatively impacted those with chronic back and leg pain

March 23, 2022 By Sean Whooley

Medtronic (NYSE:MDT) today released data from a survey demonstrating several struggles for those with chronic pain during the COVID-19 pandemic. The survey, commissioned by Medtronic and conducted by public opinion research firm The Harris Poll, found that 44% of current chronic back and leg pain sufferers experienced care delays during the COVID-19 pandemic despite 87% […]

Filed Under: Business/Financial News, Featured, Neurological, Neuromodulation/Neurostimulation, Pain Management Tagged With: coronavirus, COVID-19, Medtronic

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 42
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS